Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction.
Doiron, Jake E, Huijing Xia, Xiaoman Yu, Alexandra R Nevins, Kyle B LaPenna, Thomas E Sharp, Traci T Goodchild, et al. 2024. “Adjunctive Therapy With an Oral H2S Donor Provides Additional Therapeutic Benefit Beyond SGLT2 Inhibition in Cardiometabolic Heart Failure With Preserved Ejection Fraction.”. British Journal of Pharmacology 181 (21): 4294-4310.